Citigroup Cuts Amrize (NYSE:AMRZ) Price Target to $50.00

Posted by Francis Steltz on Oct 2nd, 2026

Amrize (NYSE:AMRZ – Get Free Report) had its target price dropped by analysts at Citigroup from $58.00 to $50.00 in a report issued on Friday, Benzinga reports. The brokerage presently has a “buy” rating on the stock. Citigroup’s price target points to a potential upside of 33.32% from the company’s current price.

Several other brokerages have also commented on AMRZ. DA Davidson initiated coverage on Amrize in a research report on Monday, August 24th. They set a “neutral” rating and a $50.00 price objective on the stock. Royal Bank Of Canada lowered shares of Amrize from a “sector perform” rating to an “underperform” rating and reduced their target price for the company from $60.00 to $48.00 in a report on Monday, August 10th. Stephens cut their price target on shares of Amrize from $65.00 to $54.00 and set an “overweight” rating for the company in a research report on Wednesday, August 12th. Morgan Stanley set a $63.00 target price on Amrize and gave the company an “overweight” rating in a report on Monday, June 22nd. Finally, Sanford C. Bernstein reaffirmed an “outperform” rating and set a $60.00 price objective on shares of Amrize in a research report on Monday, September 21st. One investment analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, eight have issued a Hold rating and three have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Amrize has an average rating of “Hold” and a consensus target price of $52.76.

Get Our Latest Stock Report on AMRZ

Amrize Price Performance

Shares of AMRZ stock traded up $0.26 during trading on Friday, hitting $37.51. The company had a trading volume of 2,168,691 shares, compared to its average volume of 3,373,587. The stock’s 50-day moving average is $43.88 and its two-hundred day moving average is $50.20. The stock has a market capitalization of $20.74 billion, a price-to-earnings ratio of 17.27, a price-to-earnings-growth ratio of 1.31 and a beta of 0.21. The company has a quick ratio of 0.73, a current ratio of 1.10 and a debt-to-equity ratio of 0.33. Amrize has a 52 week low of $36.55 and a 52 week high of $65.94.

Amrize (NYSE:AMRZ – Get Free Report) last posted its quarterly earnings data on Thursday, August 6th. The company reported $0.88 earnings per share for the quarter, missing the consensus estimate of $0.92 by ($0.04). Amrize had a net margin of 9.89% and a return on equity of 10.22%. The company had revenue of $3.49 billion for the quarter. As a group, analysts predict that Amrize will post 2.46 EPS for the current fiscal year.

Insider Buying and Selling at Amrize

In other Amrize news, Director Jacques Sanche acquired 4,150 shares of the stock in a transaction dated Wednesday, August 26th. The shares were acquired at an average cost of $45.02 per share, for a total transaction of $186,833.00. Following the completion of the transaction, the director directly owned 9,766 shares of the company’s stock, valued at approximately $439,665.32. The trade was a 73.90% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CFO Baris Oran purchased 3,000 shares of the stock in a transaction that occurred on Tuesday, August 11th. The stock was acquired at an average cost of $47.38 per share, for a total transaction of $142,140.00. Following the completion of the acquisition, the chief financial officer owned 3,000 shares in the company, valued at $142,140. This represents a ∞ increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Over the last quarter, insiders purchased 48,983 shares of company stock valued at $2,158,755. 0.54% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Amrize

Institutional investors and hedge funds have recently modified their holdings of the stock. Barclays PLC lifted its stake in Amrize by 95.4% in the fourth quarter. Barclays PLC now owns 4,614,593 shares of the company’s stock worth $249,557,000 after purchasing an additional 2,253,431 shares during the last quarter. DJE Kapital AG grew its stake in shares of Amrize by 2,005.4% during the fourth quarter. DJE Kapital AG now owns 762,887 shares of the company’s stock valued at $41,986,000 after buying an additional 726,652 shares during the last quarter. First Manhattan CO. LLC. grew its stake in shares of Amrize by 20.0% during the fourth quarter. First Manhattan CO. LLC. now owns 4,036,704 shares of the company’s stock valued at $218,305,000 after buying an additional 672,030 shares during the last quarter. River Road Asset Management LLC raised its holdings in shares of Amrize by 26.1% in the fourth quarter. River Road Asset Management LLC now owns 2,883,536 shares of the company’s stock worth $155,942,000 after buying an additional 597,542 shares during the period. Finally, Amundi lifted its stake in shares of Amrize by 30.9% during the 1st quarter. Amundi now owns 1,654,739 shares of the company’s stock worth $92,698,000 after acquiring an additional 390,750 shares during the last quarter.

About Amrize

(Get Free Report)

Amrize Ltd. is a North American building solutions company that produces and supplies essential construction materials and related products. Its portfolio includes cement, aggregates, ready-mix concrete, asphalt, concrete products and roofing systems used in residential, commercial and infrastructure projects.

The company serves customers across the United States and Canada through a network of production facilities, distribution locations and other operating sites. Its products support a range of construction applications, including roads, bridges, buildings, homes and other major infrastructure.

Amrize was established as the result of the separation of Holcim’s North American business and began operating as an independent, publicly traded company in 2025.